ReviewJournal of neuroinflammation2022
Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression.
Review in Journal of neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 296 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
296 citing papers in PubMed, 8 syntheses or guidelines pooled it, 493 citations in OpenAlex.
- Multimodal microglial and kynurenine pathway alterations across the affective-psychosis spectrum: a systematic review of patterns, heterogeneity, and dimensional implications.Molecular psychiatry · 2026Pooled it
- Therapeutic potential of AdipoRon in cognitive, depressive, and anxiety disorders: a systematic review and meta-analysis.Molecular brain · 2026Pooled it
- Associations Between Depressive Symptoms and Memory Functions in Persons with HIV: A Systematic Review and Meta-Analysis.Neuropsychology review · 2026Pooled it
- Bidirectional Mendelian Randomization and Colocalization Study of Memory B Cells and Major Depressive Disorder.Current medical science · 2026Pooled it
- Immunological landscape of nanotechnology-based depression research: a bibliometric analysis of neuroinflammation and immune modulation.Frontiers in immunology · 2026Pooled it
- Shared neuroimaging and molecular profiles in type 2 diabetes mellitus and major depressive disorder: an integrative analysis of genetic, transcriptomic, and neuroimaging data.Translational psychiatry · 2025Pooled it
- A meta-analysis on the incidence rate of depression in Chinese menopausal women.BMC psychiatry · 2025Pooled it
- Translational interdisciplinary research on human chorionic gonadotropin's enhancement of neuroendocrine crosstalk: a novel medical hypothesis for systemic adjunctive treatment of psychiatric disorders.Frontiers in psychiatry · 2025Pooled it
- Ferroptosis in major depressive disorder: Molecular mechanisms, cellular vulnerability, and therapeutic opportunities.Biochemistry and biophysics reports · 2026Review
- Initiation of SGLT2 Inhibitors Versus DPP-4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims-Based Active-Comparator New-User Study.Diabetes, obesity & metabolism · 2026Article
- The monocyte-to-HDL cholesterol ratio (MHR) modifies the association between dietary patterns and depression: a sex-specific analysis.European archives of psychiatry and clinical neuroscience · 2026Article
- TNF-dependent regulation of synaptic plasticity and neuronal activity: implications for psychiatric disorders.Molecular psychiatry · 2026Review
- Engineering Advanced Nanomedicine Against Depression: From Treatment Challenges to Delivery Strategies.Advanced healthcare materials · 2026Review
- Activation of peripheral muscarinic receptors rescues depressive-like behaviors via gut-brain-axis, involving parasympathetic excitation.Acta pharmacologica Sinica · 2026Article
- Metformin improves chronic rhinosinusitis with depressive-like behavior in mice by targeting TCF4 to inhibit the TLR4/NF-κB pathway.Scientific reports · 2026Article
- Low Dose Ketamine Preconditions Astrocyte Mitochondria to Achieve Antidepressant Efficacy via Adenosine, Humanin, and Melatonin Upregulation and Efflux.Alpha psychiatry · 2026Article
- TrkB promotes the neuronal secretion of soluble Siglec-2 (CD22) to mitigate microglial activation and alleviate depression-like behaviors in male mice.Molecular psychiatry · 2026Article
- Cytokine-mediated immune-to-brain signaling in neural circuit disorders.Experimental & molecular medicine · 2026Review
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- Aspirin alleviates long-term high-fat diet-induced depressive-like behavior in male mice via suppressing arachidonic acid-mediated microglial activation and neuroinflammation.Molecular psychiatry · 2026Article
236 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Major depressive disorder is a highly debilitating psychiatric disorder involving the dysfunction of different cell types in the brain. Microglia are the predominant resident immune cells in the brain and exhibit a critical role in depression. Recent studies have suggested that depression can be regarded as a microglial disease. Microglia regulate inflammation, synaptic plasticity, and the formation of neural networks, all of which affect depression. In this review, we highlighted the role of microglia in the pathology of depression. First, we described microglial activation in animal models and clinically depressed patients. Second, we emphasized the possible mechanisms by which microglia recognize depression-associated stress and regulate conditions. Third, we described how antidepressants (clinical medicines and natural products) affect microglial activation. Thus, this review aimed to objectively analyze the role of microglia in depression and focus on potential antidepressants. These data suggested that regulation of microglial actions might be a novel therapeutic strategy to counteract the adverse effects of devastating mental disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.